Tools
Tools
Spanu, D, Pretta, A, Lai, E, Persano, M, Donisi, C, Mariani, S, Dubois, M, Migliari, M, Saba, G, Ziranu, P, Pusceddu, V, Puzzoni, M, Astara, G and Scartozzi, M (2022) Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment. World Journal of Hepatology, 14 (7). pp. 1319-1332. ISSN 1948-5182
|
Text
Hepatocellular carcinoma and microbiota Implications for clinical management and treatment.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (990kB) | Preview |
Abstract
Gut microbiota plays an essential role in host homeostasis. It is involved in several physiological processes such as nutrients digestion and absorption, maintenance of intestinal epithelial barrier integrity and immune system self-tolerance. Especially the gut microbiota is assumed to play a crucial role in many gastrointestinal, pancreatic and liver disorders. Its role in hepatic carcinogenesis is also gaining increasing interest, especially regarding the development of therapeutic strategies. Different studies are highlighting a link between some bacterial strains and liver disease, including hepatocellular carcinoma (HCC). Indeed, HCC represents an interesting field of research in this perspective, due to the gut-liver axis, to the implication of microbiota in the immune system and to the increasing number of immunotherapy agents investigated in this tumour. Thus, the assessment of the role of microbiota in influencing clinical outcome for patients treated with these drugs is becoming of increasing importance. Our review aims to give an overview on the relationship between microbiota and HCC development/progression and treatment. We focus on potential implications on the available treatment strategies and those under study in the various stages of disease. We highlight the pathogenic mechanisms and investigate the underlying molecular pathways involved. Moreover, we investigate the potential prognostic and/or predictive role of microbiota for target therapies, immune checkpoint inhibitors and loco-regional treatment. Finally, given the limitation of current treatments, we analyze the gut microbiota-mediated therapies and its potential options for HCC treatment focusing on fecal microbiota transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Hepatocellular carcinoma; Gut microbiota; Gut-liver axis; Fecal microbiota transplantation; Carcinogenesis; Immune checkpoint inhibitors; Carcinogenesis; Fecal microbiota transplantation; Gut microbiota; Gut–liver axis; Hepatocellular carcinoma; Immune checkpoint inhibitors; Liver Cancer; Chronic Liver Disease and Cirrhosis; Cancer; Liver Disease; Microbiome; Rare Diseases; Nutrition; Orphan Drug; Digestive Diseases; 5.1 Pharmaceuticals; 2.1 Biological and endogenous factors; Oral and gastrointestinal; Cancer |
| Subjects: | G Geography. Anthropology. Recreation > GE Environmental Sciences Q Science > QH Natural history > QH301 Biology |
| Divisions: | Biological and Environmental Sciences (from Sep 19) |
| Publisher: | Baishideng Publishing Group Inc. |
| SWORD Depositor: | A Symplectic |
| Date Deposited: | 28 Nov 2024 15:28 |
| Last Modified: | 28 Nov 2024 15:30 |
| DOI or ID number: | 10.4254/wjh.v14.i7.1319 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/24926 |
 |
View Item |